Portfolio

Acerta Pharma www.acerta-pharma.com

Location Oss (The Netherlands)
Fund BioGeneration Ventures II B.V.
Year 2013
Status Realized
Acerta Pharma develops novel therapeutics in oncology and autoimmune diseases.

Arcarios www.arcarios.com

Location Rotterdam (The Netherlands), Diepenbeek (Belgium)
Fund BioGeneration Ventures B.V.
Year 2010
Status Divested
Arcarios develops novel therapeutics for bone and joint diseases.

arGEN-X www.argen-x.com

Location Rotterdam (The Netherlands), Gent (Belgium)
Fund BioGeneration Ventures B.V.
Year 2009
Status Realized
arGEN-X employs a superior therapeutic antibody platform for the generation of human monoclonal antibodies.

BioCeros www.bioceros.com

Location Utrecht (The Netherlands)
Fund BioGeneration Ventures B.V.
Year 2008
Status Realized
Bioceros offers cell line generation services related to the preclinical development of monoclonal antibodies and generation of GMP-ready protein producing cell lines.

Cristal Therapeutics www.cristaltherapeutics.com

Location Maastricht (The Netherlands)
Fund BioGeneration Ventures II B.V.
Year 2012
Status Active
Cristal Therapeutics develops, a new class of nanomedicines based on its proprietary polymeric technologies with an optimized drug disposition and a more favorable tolerability profile.

Dezima Pharma

Location Amsterdam (The Netherlands)
Fund BioGeneration Ventures II B.V.
Year 2012
Status Realized
Dezima Pharma develops a best in class CETP inibitor for the treatment of cardiovascular disease.

EPD-vision www.epd-vision.nl

Location Leiden (The Netherlands)
Fund BioGeneration Ventures B.V.
Year 2009
Status Active
EPD-vision makes an integrated software solution available for cardiologists developed at the department of cardiology of the LUMC, Leiden.

FlexGen 

Location Leiden (The Netherlands)
Fund BioGeneration Ventures B.V.
Year 2009
Status Divested
Flexgen develops novel aptamer compounds based on its proprietary flexible array technology.

Lanthio Pharma www.lanthiopharma.com

Location Groningen (The Netherlands)
Fund BioGeneration Ventures B.V.
Year 2012
Status Realized
Lanthio Pharma discovers and develops Lanthiopeptides, a new class of peptides with high target selectivity and improved "drug-like" properties.

Medisse 

Location Ede (The Netherlands)
Fund BioGeneration Ventures B.V.
Year 2009
Satus Divested
Medisse is developing an array of resorbable implants based on its proprietary PTMC – polymer platform.

Mucosis www.mucosis.com

Location Groningen (The Netherlands)
Fund BioGeneration Ventures B.V.
Year 2007
Status Active
Mucosis is developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth.

NovioGendix 

Location Nijmegen (The Netherlands)
Fund BioGeneration Ventures B.V.
Year 2007
Satus Realized
NovioGendix is developing a new biomarker panel for the detection and management of prostate cancer and other cancers.

Progentix Orthobiology www.progentix.com

Location Bilthoven (The Netherlands)
Fund BioGeneration Ventures B.V.
Year 2008
Status Realized
Progentix Orthobiology is developing synthetic bone substitutes designed to accelerate bone healing through a novel micro-structure.

SurgVision www.surgvision.com

Location 't Harde (The Netherlands)
Fund BioGeneration Ventures II B.V.
Year 2013
Status Active
SurgVision develops fluoresence imaging systems including tracers for use in image guided surgery, e.g., in breastcancer.
   

Synaffix   www.synaffix.com

Location Oss (The Netherlands)
Fund BioGeneration Ventures II B.V.
Year 2013
Status Active
Synaffix BV develops a next generation ADC platform.
 
Desktop versie